Teva Pharmaceutical Industries (NYSE:TEVA) Receiving Extremely Negative Press Coverage, Study Shows

Share on StockTwits

Headlines about Teva Pharmaceutical Industries (NYSE:TEVA) have trended extremely negative this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of -4.57 on their scale. InfoTrie also gave media headlines about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Teva Pharmaceutical Industries’ analysis:

Teva Pharmaceutical Industries stock opened at $7.93 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $6.07 and a 12 month high of $23.97. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The business’s 50 day simple moving average is $7.26 and its 200 day simple moving average is $9.40. The company has a market cap of $8.90 billion, a price-to-earnings ratio of 2.83, a PEG ratio of 0.85 and a beta of 1.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The business had revenue of $4.34 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 7.7% on a year-over-year basis. As a group, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on TEVA shares. UBS Group set a $8.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Friday, August 16th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. BMO Capital Markets reduced their target price on Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. Finally, Wolfe Research started coverage on Teva Pharmaceutical Industries in a report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 target price for the company. Six equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $11.17.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: S&P 500 Index

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.